0001746473-24-000005.txt : 20240119
0001746473-24-000005.hdr.sgml : 20240119
20240119171932
ACCESSION NUMBER: 0001746473-24-000005
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240117
FILED AS OF DATE: 20240119
DATE AS OF CHANGE: 20240119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cummings Keith Lamont
CENTRAL INDEX KEY: 0001809204
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39303
FILM NUMBER: 24546472
MAIL ADDRESS:
STREET 1: C/O PLIANT THERAPEUTICS, INC.
STREET 2: 260 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PLIANT THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001746473
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 474272481
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 260 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-481-6770
MAIL ADDRESS:
STREET 1: 260 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
wk-form4_1705702764.xml
FORM 4
X0508
4
2024-01-17
0
0001746473
PLIANT THERAPEUTICS, INC.
PLRX
0001809204
Cummings Keith Lamont
C/O PLIANT THERAPEUTICS, INC.
260 LITTLEFIELD AVENUE
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Financial Officer
1
Common Stock
2024-01-17
4
S
0
9781
17.23
D
194605
D
Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $16.33 to $17.90, inclusive, between January 17, 2024 and January 18, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.
Includes 387 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.
/s/Mike Ouimette, attorney-in-fact
2024-01-19